Apixaban

證據等級: L5

預測適應症: 1 個

Apixaban: Evidence Pack Incomplete — No Repurposing Candidates Identified

One-Sentence Summary

Apixaban is a direct oral anticoagulant (Factor Xa inhibitor), widely used internationally for stroke prevention in atrial fibrillation and venous thromboembolism (VTE) treatment. The current Evidence Pack (v4) returned zero TxGNN-predicted new indications, and critical inputs — including mechanism of action and safety data — remain unresolved. This report is a triage placeholder; a full repurposing evaluation cannot proceed until the data gaps are remediated.

Quick Overview

Item	Content
Original Indication	Not available in Evidence Pack
Predicted New Indication	None identified
TxGNN Prediction Score	N/A
Evidence Level	— (no predictions to evaluate)
Taiwan Market Status	未上市 (Not marketed)
Number of Authorizations	0
Recommended Decision	Hold

Why No Predictions Are Available

The TxGNN model returned an empty predicted_indications list for Apixaban. Based on the query log, DrugBank was successfully queried (result_count: 1) but the pipeline did not produce scored candidates. Three likely causes:

Missing original indications: The original_indications field is empty, which may have caused the disease–drug graph traversal to start from an undefined anchor point, producing no candidate paths.
MOA gap (DG002, High severity): Without mechanism of action data, TxGNN cannot build the mechanism-level similarity features used to score candidate disease links.
Safety gate not cleared (DG001, Blocking severity): The TFDA package insert query returned a result but the warnings/contraindications were not parsed into the Evidence Pack. This blocking gap prevents the pipeline from advancing to safety pre-screening (S1), which may have halted the full workflow.

Until all blocking gaps are resolved and the TxGNN run is re-executed, no drug repurposing candidates can be evaluated.

Taiwan Market Information

Apixaban has no registered marketing authorizations with the Taiwan FDA (TFDA). The drug is not commercially marketed in Taiwan under any product name as of the data cutoff (2026-04-20).

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Two unresolved data gaps — one Blocking (DG001: TFDA package insert safety data) and one High (DG002: MOA) — prevent even a preliminary evaluation. Additionally, the TxGNN model produced zero predictions, meaning there is no repurposing hypothesis to assess at this time.

To proceed, the following is needed:

Re-run TxGNN pipeline after resolving DG001 and DG002 — the predicted_indications array must be populated before any evaluation can begin
Resolve DG001 (Blocking): Download and parse the TFDA package insert PDF to extract warnings and contraindications; this is required for S1 safety pre-screening
Resolve DG002 (High): Query DrugBank API for Apixaban's mechanism of action (Factor Xa inhibition pathway) and populate original_moa
Populate original_indications: Add the approved indication list (e.g., stroke prevention in non-valvular AFib, VTE treatment/prophylaxis) to provide TxGNN with correct graph anchor nodes
Re-run DDI query: The DDI lookup returned not_found; verify whether this reflects a true absence of interaction data or a query failure
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.